Johnson & Johnson Reports Mixed Q1 Results, Adjusts Full-Year Guidance

Despite beating earnings per share estimates, Johnson & Johnson's Q1 revenue slightly missed expectations, leading to a modest stock dip.

Johnson & Johnson's Q1 revenue reached $21.38 billion, narrowly missing the $21.4 billion forecast by analysts.
The company reported adjusted earnings of $2.71 per share, surpassing the expected $2.64.
Investments in cardiovascular medical devices contributed to revenue growth, but overall sales fell short of Wall Street predictions.
Johnson & Johnson has adjusted its full-year guidance, now expecting sales between $88 billion and $88.4 billion and earnings per share from $10.57 to $10.72.
The stock experienced a 2% decline following the earnings announcement, reflecting investor reactions to the mixed financial results.